Vantis Health has completed a €10m ($10.9m) Series A funding round led by Angelini Ventures’, the investment arm of Italian industrial group Angelini Industries.
The German digital health company aims to address concerns in Germany of a shortfall in healthcare practitioners by advancing primary care, particularly for chronic diseases, through a combination of digital technologies and applications for optimising practice management.
Research indicates that over 36% of general practitioners (GPs) in Germany are over 60 years old and, in the next three years, it is estimated that their retirement will lead to the closure of between five and eight thousand doctors’ practices across the nation.
Vantis said the funds would go towards the continued development of its data-driven approach to chronic disease management and help to advance the company’s use of telemedicine, continuous monitoring, digital therapies, and AI-powered processes.
Describing Vantis’s plans as “redefining primary care”, principal in digital health at Angelini Ventures, Nils Bottler said the company’s model holds the potential to address similar healthcare challenges across Europe and that its vision aligns with Angelini Ventures’ commitment to support companies bringing “tangible, technology-enabled improvement to healthcare”.
The funding round also included participation from Bayern Kapital, Twip Impact Ventures, and existing investors firstminute and b2venture.
Related: Neuromod raises $10.9m to support neuromod for tinnitus
Vantis Health co-founder and CEO Till Jansen commented: “As a software company with our own practices, we have the unique ability to tailor our technology to the current challenges in primary care and continuously optimise it.
“Our goal is to achieve better treatment outcomes for patients while simplifying doctors’ daily routines.”
Angelini Ventures was launched in 2022 with a €300m capital commitment. To date, the venture capital arm has invested €100m into 18 companies including biotechs Cour Pharmaceuticals and Freya Biosciences, and digital health companies Cadence Neuroscience and Nobi.
Also this month, European life sciences venture capital company Sofinnova Partners revealed that its total assets under management had risen to over €4bn ($4.3bn).
Last year Symbiotic Capital, an initiative co-chaired by serial biotech entrepreneur Arie Belldegrun, founder of Kite Pharma and co-founder of Bellco Capital, launched a fund of more than $600m for life science-specific loans.
